Accelerate Diagnostics (NASDAQ:AXDX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report sent to investors on Friday. The firm issued a hold rating on the medical research company’s stock.

AXDX has been the subject of a number of other research reports. William Blair reissued an outperform rating on shares of Accelerate Diagnostics in a research report on Tuesday, April 2nd. Craig Hallum decreased their target price on Accelerate Diagnostics from $2.00 to $1.00 and set a hold rating for the company in a research report on Monday, April 1st.

Accelerate Diagnostics Stock Down 1.5 %

AXDX stock opened at $0.88 on Friday. Accelerate Diagnostics has a 52-week low of $0.83 and a 52-week high of $11.90. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $3.27. The stock has a market capitalization of $18.95 million, a price-to-earnings ratio of -0.18 and a beta of 0.52.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sonora Investment Management Group LLC acquired a new position in Accelerate Diagnostics in the 3rd quarter worth $63,000. Swiss National Bank lifted its stake in shares of Accelerate Diagnostics by 19.0% in the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after acquiring an additional 13,600 shares in the last quarter. Tejara Capital Ltd purchased a new position in Accelerate Diagnostics in the third quarter valued at about $78,000. Virtu Financial LLC grew its stake in Accelerate Diagnostics by 95.4% during the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 17,461 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in Accelerate Diagnostics during the 1st quarter worth approximately $27,000. 17.14% of the stock is currently owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.